grinboss

Agilent Technologies

A

What is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.

At $177.33 (close on November 18) and with the other assumptions at their starting point, Agilent Technologies's sales would need to grow 19.2% a year for ten years; over its last decade, the median was 5.7%. Value it with your own assumptions.

Its accounts, year by year

Year endSalesGrowthMargin
10/20154,038—14.3%
10/20164,2024.1%16.0%
10/20174,4726.4%19.4%
10/20184,9149.9%19.8%
10/20195,1635.1%19.6%
10/20205,3393.4%17.4%
10/20216,31918.4%23.1%
10/20226,8488.4%25.5%
10/20236,833−0.2%21.4%
10/20246,510−4.7%24.8%
10/20256,9486.7%23.1%

Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Agilent Technologies files with the SEC, the US securities regulator; the latest is for the fiscal year ended October 31, 2025. See the report.

The model's starting point

  • Sales growth, years 1 to 10: 6.7% a year.
  • Sales growth after year 10: 2.5% a year.
  • Operating margin, before stock pay: 23.1% of sales.
  • Working capital needed to grow: $10.9 per $100 of new sales.
  • Capital spending: 4.4% of sales.
  • Stock pay to employees: 2.8% of sales.
  • Discount rate, the same for every company: 10%.

These are the six assumptions the page starts with; each user moves them as they see fit.

Reference points

They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.

For

  • Over ten years, its worst fall from a high was 45%; the median is 56%.
  • Its margin has risen over these years, from 16% to 23%.
  • It makes $23 of operating profit for every $100 it sells, before stock pay; the median is $18.
  • It generated free cash flow in each of the last 5 years.

Against

  • It is one of the smallest in grinboss: it sells $6.9 billion a year; the median is $15.1 billion.
  • It ties up $11 in inventory and unpaid customer bills for every $100 of new sales, more than the median ($2).
  • Its stock pay to employees comes to 2.8% of sales, more than the median (1.5%). That is a part of the company that stops belonging to the shareholders.
  • Its growth has slowed: −0.2% a year in the last three fiscal years, against 5.8% over the whole decade.

Next results: November 23, 2026.

Other companies in its sector (Health Care)

AbbVie (ABBV) · Abbott Laboratories (ABT) · Align Technology (ALGN) · Alnylam Pharmaceuticals (ALNY) · Amgen (AMGN) · Baxter International (BAX) · Becton Dickinson (BDX) · Biogen (BIIB) · All companies

Loading the model…